261 related articles for article (PubMed ID: 34878645)
1. Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.
Luengas-Martinez A; Paus R; Young HS
Br J Dermatol; 2022 May; 186(5):782-791. PubMed ID: 34878645
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
Canavese M; Altruda F; Ruzicka T; Schauber J
J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis.
Luengas-Martinez A; Hardman-Smart J; Paus R; Young HS
Exp Dermatol; 2020 Aug; 29(8):687-698. PubMed ID: 32654325
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis.
Midde HS; Priyadarssini M; Rajappa M; Munisamy M; Mohan Raj PS; Singh S; Priyadarshini G
Clin Exp Dermatol; 2021 Jan; 46(1):50-57. PubMed ID: 32516443
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Liu JH; Wu HH; Zhao YK; Wang F; Gao Q; Luo DQ
Curr Vasc Pharmacol; 2018; 16(5):510-521. PubMed ID: 28982338
[TBL] [Abstract][Full Text] [Related]
6. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis.
Bhushan M; McLaughlin B; Weiss JB; Griffiths CE
Br J Dermatol; 1999 Dec; 141(6):1054-60. PubMed ID: 10606852
[TBL] [Abstract][Full Text] [Related]
7. Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.
Malecic N; Young HS
Expert Opin Investig Drugs; 2016; 25(4):455-62. PubMed ID: 26864055
[TBL] [Abstract][Full Text] [Related]
8. Investigational VEGF antagonists for psoriasis.
Crawshaw AA; Griffiths CE; Young HS
Expert Opin Investig Drugs; 2012 Jan; 21(1):33-43. PubMed ID: 22088218
[TBL] [Abstract][Full Text] [Related]
9. Targeting VEGF/VEGFR in the treatment of psoriasis.
Li W; Man XY; Chen JQ; Zhou J; Cai SQ; Zheng M
Discov Med; 2014 Sep; 18(98):97-104. PubMed ID: 25227750
[TBL] [Abstract][Full Text] [Related]
10. Clinical, pathological and immunological features of psoriatic-like lesions affecting keratin 14-vascular endothelial growth factor transgenic mice.
Canavese M; Altruda F; Silengo L; Castiglioni V; Scanziani E; Radaelli E
Histol Histopathol; 2011 Mar; 26(3):285-96. PubMed ID: 21210341
[TBL] [Abstract][Full Text] [Related]
11. Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation.
Wen J; Pei H; Wang X; Xie C; Li S; Huang L; Qiu N; Wang W; Cheng X; Chen L
J Dermatol Sci; 2014 Jun; 74(3):242-50. PubMed ID: 24685902
[TBL] [Abstract][Full Text] [Related]
12. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis.
Hvid H; Teige I; Kvist PH; Svensson L; Kemp K
Int Immunol; 2008 Aug; 20(8):1097-106. PubMed ID: 18579711
[TBL] [Abstract][Full Text] [Related]
13. Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia.
Malecic N; Young HS
Exp Dermatol; 2017 Apr; 26(4):299-304. PubMed ID: 28156019
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
15. Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model.
Ren X; Li J; Zhou X; Luo X; Huang N; Wang Y; Chen X; Wei Y
Dermatology; 2009; 219(3):232-8. PubMed ID: 19729876
[TBL] [Abstract][Full Text] [Related]
16. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
17. Ginsenoside Rh2 Suppresses Neovascularization in Xenograft Psoriasis Model.
Zhou J; Gao Y; Yi X; Ding Y
Cell Physiol Biochem; 2015; 36(3):980-7. PubMed ID: 26087848
[TBL] [Abstract][Full Text] [Related]
18. Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis.
Henno A; Blacher S; Lambert CA; Deroanne C; Noël A; Lapière C; de la Brassinne M; Nusgens BV; Colige A
J Dermatol Sci; 2010 Mar; 57(3):162-9. PubMed ID: 20071151
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis.
Weidemann AK; Crawshaw AA; Byrne E; Young HS
Clin Cosmet Investig Dermatol; 2013 Sep; 6():233-44. PubMed ID: 24101875
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of vascular endothelial growth factor-A downregulates angiogenesis in psoriasis: A pilot study.
Luengas-Martinez A; Ismail D; Paus R; Young HS
Skin Health Dis; 2023 Oct; 3(5):e245. PubMed ID: 37799359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
